A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis (REFINE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03222609 |
Recruitment Status :
Active, not recruiting
First Posted : July 19, 2017
Last Update Posted : March 3, 2023
|
Sponsor:
AbbVie
Information provided by (Responsible Party):
AbbVie
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Actual Primary Completion Date : | March 28, 2022 |
Estimated Study Completion Date : | February 2, 2029 |
Certification/Extension First Submitted : | March 1, 2023 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):